GlassScriptPhysician profile
William Jacob Cobb
NPI 1346771441
$7,112.37
in general payments reported to CMS, 2019-2025
47 companies · $1,515 in 2025
The $1,515 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.06 · 2021: $480 · 2022: $1,384 · 2023: $1,891 · 2024: $1,830 · 2025: $1,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,151 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,151.20 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $986.23 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $610.31 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $596.75 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $493.27 | 2023-2025 | |
| Lilly USA, LLC | $424.53 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $414.26 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Corium, LLC | $390.54 | 2021-2025 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $365.05 | 2021-2025 | Jardiance |
| Amgen INC. | $305.47 | 2021-2025 | Otezla, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $213.81 | 2023-2025 | Rexulti |
| Astellas Pharma US INC | $195.00 | 2023-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $188.24 | 2021-2024 | Belsomra, Gardasil 9, Vaxneuvance |
| Sanofi-Aventis U.S. LLC | $166.92 | 2021-2023 | |
| Axsome Therapeutics, INC. | $147.59 | 2024 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.61 | 2021-2025 | Xifaxan, Trulance |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cobb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.